Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: An assessment of long-term comparative effectiveness and safety

Journal of Clinical Psychopharmacology

Volumn 30, Issue 3, 2010, Pages 225-229

  Byers, Melanie G ^a   Allison, Kristen M ^a   Wendel, Christopher S ^a   Lee, Jeannie K ^b  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Adrenergic antagonist; Atypical antipsychotic; Nighttime symptoms; Posttraumatic stress disorder; Prazosin; Quetiapine

Indexed keywords

PRAZOSIN; QUETIAPINE;

ADULT; ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NIGHT; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATIENT ATTITUDE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VETERAN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARIZONA; COHORT STUDIES; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PRAZOSIN; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SLEEP DISORDERS; STRESS DISORDERS, POST-TRAUMATIC; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS; YOUNG ADULT;

EID: 77952331255     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181dac52f     Document Type: Article

References (12)

1. Spoormaker VI, Montgomery P. Disturbed sleep in post-traumatic stress disorder: secondary symptom or core feature? Sleep Med Rev. 2008;12:169-184.
2. Geracioti TD, Baker DG, Ekhator NN, et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry. 2001;158:1227-1230.
3. Raskind MA, Peskind ER, Hoff DJ, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbances in combat veterans with post-traumatic stress disorder. Biol Psychiatry. 2007;61:928-934.
4. Mellman TA, Bustamante V, Fins AI, et al. REM sleep and the early development of posttraumatic stress disorder. Am J Psychiatry. 2002;159:1696-1701.
5. Hamner MB, Diamond BI. Elevated plasma dopamine in posttraumatic stress disorder: a preliminary report. Biol Psychiatry. 1993;33:304-306.
6. Ahearn EP, Krohn A, Connor KM, et al. Pharmacologic treatment of posttraumatic stress disorder: a focus on antipsychotic use. Ann Clin Psychiatry. 2003;15:193-201.
7. Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160:371-373.
8. Raskind MA, Thompson C, Petrie EC, et al. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. J Clin Psychiatry. 2002;63:565-568.
9. Hamner MB, Deitsch SE, Brodrick PS, et al. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol. 2003;23:15-20.
10. Ahearn EP, Mussey M, Johnson C, et al. Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. Int Clin Psychopharmacol. 2006;21:29-33.
11. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334-1349.
12. Dunayevich E, Ascher-Svanum H, Zhao F, et al. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry. 2007;68:1163-1171.